Security key
36322Q107
Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (GLTO)
CUSIP: 36322Q107
Q4 2021 13F Holders as of 31 Dec 2021
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Total 13F shares
- 10,056,300
- Total 13F value
- $30,470,000
- Share change
- -341,974
- SEC-reported price per share
- $3.03
- Number of holders
- 24
- Value change
- -$1,059,530
- Number of buys
- 11
- Number of sells
- 11
- Shares outstanding
- 59,685,400
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2021
Institutions
24
Top holders
10
GLTO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2022
Previous quarter: Q3 2021
Damora Therapeutics, Inc. SEC filings
Damora Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36322Q107
Recent filing periods:
Ownership snapshot
Top reported holders of GLTO - Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2021
13F
Lead comparable stake: 6.9%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 6.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
6.9%
Novo Holdings A/S
4.2%
Janus Henderson Group Ltd.
2.2%
Cormorant Asset Management, LP
1.9%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
0.47%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
6.9%
|
$14,686,000
4,090,937 shares
|
— | 30 Sep 2021 |
| Novo Holdings A/S |
13F
Company
|
4.2%
|
$8,967,000
2,497,791 shares
|
— | 30 Sep 2021 |
| Janus Henderson Group Ltd. |
13F
Company
|
2.2%
|
$4,496,000
1,286,007 shares
|
— | 30 Sep 2021 |
| Cormorant Asset Management, LP |
13F
Company
|
1.9%
|
$4,131,000
1,150,730 shares
|
— | 30 Sep 2021 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.47%
|
$1,016,000
283,100 shares
|
— | 30 Sep 2021 |
| TWO SIGMA ADVISERS, LP |
13F
Company
|
0.41%
|
$874,000
243,500 shares
|
— | 30 Sep 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2021
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
24
Shares
10,056,300
Rows available
24
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2021 vs Q3 2021 Across Filers
Q3 2021 holders
25
Q4 2021 holders
24
Holder diff
-1
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 value | Q4 2021 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend